...Next steps could include optimizing and testing the compounds in the models. Heidelberg Pharma AG, Link Health Group...

...a KSP inhibitor, in Phase II testing to treat multiple myeloma (MM). 4SC AG and Link Health Group...

...filanesib ( ARRY-520 ) in Phase II testing for multiple myeloma (MM). 4SC AG and Link Health Group...

...4SC granted Link Health exclusive rights to develop and commercialize 4SC-205 in Taiwan and China, including Hong...
...rights to develop and commercialize 4SC-205 in Taiwan and China, including Hong Kong and Macau. Link Health...
...disclose additional details, and Link Health did not respond to inquiries. 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Link Health Group...

...4SC AG (Xetra:VSC) granted Link Health Group (Guangzhou, China) exclusive rights to oncology candidate 4SC-205 in China, Hong...
...Guangzhou, China) exclusive rights to oncology candidate 4SC-205 in China, Hong Kong, Taiwan and Macau. Link Health...
...it is seeking other partners for the candidate, and may use clinical data generated by Link Health...

...side,'" Scott told BioCentury. CMS described outcomes-based risk-sharing agreements as "voluntary agreements with manufacturers to link health...

...serine protease inhibitor targeting urokinase-type plasminogen activator ( uPA ). Earlier this year, Wilex granted Link Health Group...

...Wilex granted Link Health exclusive rights to develop and commercialize Mesupron in Taiwan and China, including Hong...
...$9.6 million) for the first four indications developed by Link Health, plus staggered medium single-digit royalties. Link Health...
...partners said terms for additional indications are not disclosed. The companies said data generated by Link Health...